Anavex life sciences announces acceptance of peer-reviewed manuscript of oral blarcamesine phase iib/iii data in a reference alzheimer's disease journal

New york, nov. 25, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) diseases, today announced the acceptance of a peer-reviewed manuscript titled, “blarcamesine for the treatment of early alzheimer's disease: results from the anavex2-73-ad-004 phase iib/iii trial,” in a medical journal with focus on alzheimer's disease. the publication date is expected around q4 2024/q1 2025.
AVXL Ratings Summary
AVXL Quant Ranking